KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Interest Expenses (2016 - 2025)

Pacira BioSciences has reported Interest Expenses over the past 16 years, most recently at $3.9 million for Q4 2025.

  • Quarterly results put Interest Expenses at $3.9 million for Q4 2025, down 16.84% from a year ago — trailing twelve months through Dec 2025 was $17.4 million (up 5.29% YoY), and the annual figure for FY2025 was $17.4 million, up 5.29%.
  • Interest Expenses for Q4 2025 was $3.9 million at Pacira BioSciences, down from $4.3 million in the prior quarter.
  • Over the last five years, Interest Expenses for PCRX hit a ceiling of $11.0 million in Q4 2022 and a floor of $3.3 million in Q1 2024.
  • Median Interest Expenses over the past 5 years was $4.7 million (2024), compared with a mean of $6.3 million.
  • Biggest five-year swings in Interest Expenses: skyrocketed 47.59% in 2021 and later tumbled 69.31% in 2023.
  • Pacira BioSciences' Interest Expenses stood at $10.4 million in 2021, then increased by 5.93% to $11.0 million in 2022, then crashed by 69.31% to $3.4 million in 2023, then skyrocketed by 38.13% to $4.7 million in 2024, then dropped by 16.84% to $3.9 million in 2025.
  • The last three reported values for Interest Expenses were $3.9 million (Q4 2025), $4.3 million (Q3 2025), and $4.7 million (Q2 2025) per Business Quant data.